Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

China Biologic Products Inc reiterates FY 2014 guidance


Tuesday, 5 Aug 2014 04:45pm EDT 

China Biologic Products Inc:Reiterates FY 2014 financial forecast of total sales in the range of $230 million to $240 million and non-GAAP adjusted net income in the range of $67 million to $69 million.FY 2014 revenue of $238 million and net income of $67 million - Thomson Reuters I/B/E/S. 

Company Quote

98.59
-0.35 -0.35%
24 Apr 2015